Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1419384

Nano-drug Delivery Systems (NDDS) in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): Current Status, Prospects and Challenges

Provisionally accepted
Yang Ying Yang Ying 1,2Wang Xiaojing Wang Xiaojing 1,2*
  • 1 Department of Gastroenterology, Lishui Central Hospital, Lishui, Zhejiang Province, China
  • 2 Department of Gastroenterology, Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    About one-third of the global population suffers from metabolic dysfunction-associated steatotic liver disease (MASLD), but specific treatments for MASLD have long been lacking, primarily due to the unclear etiology of the disease. In addition to lifestyle modifications and weight loss surgery, pharmacotherapy is the most common treatment among MASLD patients, and these drugs typically target the pathogenic factors of MASLD. However, bioavailability, efficacy, and side effects all limit the maximum therapeutic potential of the drugs. With the development of nanomedicine, recent years have seen attempts to combine MASLD pharmacotherapy with nanomaterials, such as liposomes, polymer nanoparticles, micelles, and cocrystals, which effectively improves the water solubility and targeting of the drugs, thereby enhancing therapeutic efficacy and reducing toxic side effects, offering new perspectives and futures for the treatment of MASLD.

    Keywords: Metabolic dysfunction-associated steatotic liver disease, MASLD, Nano-drug delivery system, NDDS, nanocarrier, nanoparticle, Nanoliposome

    Received: 18 Apr 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Ying and Xiaojing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wang Xiaojing, Department of Gastroenterology, Lishui Central Hospital, Lishui, 323000, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.